# 1 Title: *ESR1* F404 mutations and acquired resistance to fulvestrant in *ESR1* 2 mutant breast cancer.

# 3 Authors and affiliations:

Belinda Kingston<sup>1</sup>, Alex Pearson<sup>1</sup>, Maria Teresa Herrera-Abreu<sup>1</sup>, Li Xuan Sim<sup>1</sup>,
Rosalind J Cutts<sup>1</sup>, Heena Shah<sup>1</sup>, Laura Moretti<sup>2</sup>, Lucy S Kilburn<sup>2</sup>, Hannah Johnson<sup>2</sup>,
Iain R Macpherson<sup>3</sup>, Alistair Ring<sup>4</sup>, Judith M Bliss<sup>2</sup>, Yingwei Hou<sup>5</sup>, Weiyi Toy<sup>6</sup>, John A
Katzenellenbogen<sup>5</sup>, Sarat Chandarlapaty<sup>6</sup>, Nicholas C Turner<sup>1,4</sup>

- <sup>1</sup> The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer
  9 Research, London, SW3 6JB.
- <sup>2</sup> Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, UK
- <sup>3</sup> School of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH
- <sup>4</sup> Breast Unit, The Royal Marsden Hospital, Fulham Road, London.
- <sup>5</sup> Department of Chemistry and Cancer Center at Illinois, University of Illinois at
- 14 Urbana-Champaign, Urbana, Illinois.
- <sup>6</sup> Memorial Sloan Kettering Cancer Center, New York City; Department of Medicine,
- 16 Weill Cornell Medical College, New York City, USA.
- 17 <u>Running title:</u>
- 18 Mutations of *ESR1* at F404 confer fulvestrant resistance.
- 19 Keywords:
- 20 Fulvestrant, acquired resistance, breast cancer.

# 21 Additional information.

BK is supported by Cancer Research UK Grant A25161 and Institutional funding from
Breast Cancer Now. AP, MTHA, LXS and NCT are supported by funding from Breast
Cancer Now. Research support for J.A.K. and Y.H. was provided by the National
Institutes of Health (NIH/NCI, 1R01 CA220284) and the Breast Cancer Research
Foundation (BCRF-084). SC is supported by NIH Cancer Center Support Grant P30CA008748 and NIH R01CA245069.

# 28 Corresponding author:

Prof Nicholas Turner, The Breast Cancer Now Toby Robins Research Centre, The
Institute of Cancer Research, London, SW3 6JB. nick.turner@icr.ac.uk 020 7811
8914/ext4737.

# 32 <u>Conflict of interest disclosure statement:</u>

33 BK has received a grant from Cancer Research UK, and honoraria from Guardant 34 Health outside the submitted work. AR has received honoraria for advisory boards and 35 talks: Novartis, Astra Zeneca, Daiichi-Sankyo, Roche, Pfizer, Lilly, Gilead, MSD, 36 Seagen, Stemline. IRM has paid consultancy for Roche, Novartis, Pfizer, Eli Lilly, 37 Pierre Fabre, Daiichi Sankyo, and AstraZeneca, and received travel/conference 38 expenses from Roche, Eli Lilly, and Daiichi Sankyo. SC has received research grant support from Daiichi-Sankyo, AstraZeneca, and Ambrx; financial interests in Totus 39 40 Medicines and Odyssey Biosciences; and consulting fees from Novartis, AstraZeneca, 41 Lilly, and Paige.ai. NT has received advisory board honoraria from Astra Zeneca, 42 Bristol-Myers Squibb, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, 43 Roche/Genentech, GlaxoSmithKline, Zentalis pharmaceuticals, Repare therapeutics, 44 Arvinas, Inivata and research funding from Astra Zeneca, BioRad, Pfizer,

45 Roche/Genentech, Merck Sharpe and Dohme, Guardant Health, Invitae, Inivata,
46 Personalis, Natera. AP, MTHA, LXS, RC, HS, LM, LK, HJ, JB, YH, YW, and JAK
47 declare no conflict of interest.

48

49 Word count: 4988, including 6 figures and 1 table.

# 51 Abstract

52 Fulvestrant is used to treat patients with hormone receptor positive advanced breast cancer but acquired resistance is poorly understood. PlasmaMATCH Cohort A 53 54 (NCT03182634) investigated the activity of fulvestrant in patients with activating ESR1 55 mutations in circulating tumor DNA (ctDNA). Baseline ESR1 mutations Y537S 56 associated with poor, and Y537C with good outcome. Sequencing of baseline and 57 EOT ctDNA samples (n=69) revealed 3/69 (4%) patients acquired novel ESR1 F404 58 mutations (F404L, F404I, F404V), in *cis* with activating mutations. *In silico* modelling 59 revealed that ESR1 F404 contributes to fulvestrant binding to ERa through a pi-60 stacking bond, with mutations disrupting this bond. In vitro analysis demonstrated that 61 single F404L, E380Q, and D538G models were less sensitive to fulvestrant, while 62 compound mutations D538G+F404L and E380Q+F404L were resistant. Several oral 63 ERa degraders were active against compound mutant models. We have identified a 64 resistance mechanism specific to fulvestrant, that can be targeted by treatments in 65 clinical development.

66

#### 67 Statement of significance

Novel F404 *ESR1* mutations may be acquired to cause overt resistance to fulvestrant when combined with pre-existing activating *ESR1* mutations. Novel combinations of mutations in the ER ligand binding domain may cause drug-specific resistance, emphasising the potential of similar drug-specific mutations to impact efficacy of oral ER degraders in development.

#### 74 Introduction

75 For estrogen receptor positive (ER+) breast cancer, which accounts for 75% of breast 76 cancers, hormonal therapy forms the backbone of treatment. In advanced breast 77 cancer (ABC), the selective estrogen receptor degrader (SERD) fulvestrant is licenced 78 for use in the first and second line, both as a single agent, and in combination with 79 targeted therapies including CDK4/6 inhibitors and alpelisib(1-3). Fulvestrant acts by 80 competitively inhibiting the binding of estradiol to  $ER\alpha(4)$ , impeding receptor 81 dimerization and nuclear localisation(5,6), preventing the activation of estrogen 82 response elements within the regulatory regions of estrogen sensitive genes. 83 Fulvestrant-bound ER is also unstable, leading to increased degradation of the 84 estrogen receptor(6). Although a standard therapy for patients with ABC, few studies 85 have investigated mechanisms of resistance to fulvestrant.

86 Activating estrogen receptor mutations (ESR1 mutations) are acquired through prior 87 aromatase inhibitor therapy for ABC(7), with circulating tumour DNA analysis 88 demonstrating that the mutations are present in 15-40% of patients treated with prior 89 aromatase inhibition(8-10). Activating *ESR1* mutations, that cluster at specific amino 90 acids in the ligand binding domain (LBD), result in ligand independent activation of 91 *ESR1*. Fulvestrant binding to mutant  $ER\alpha$  is partially impaired, with higher 92 concentrations of fulvestrant required to inhibit mutant ER $\alpha$  in vitro(5,11). It is 93 considered unlikely that fulvestrant achieves concentrations required to optimally 94 inhibit mutant *ESR1* in the clinic, and new oral SERDS that do fully inhibit *ESR1*, such 95 as elacestrant, have improved activity as single agents(12-14).

96 The plasmaMATCH trial investigated the activity of a range of targeted treatments in
97 patients selected based on plasma circulating tumour DNA (ctDNA) testing. Cohort A

98 enrolled patients with ER+ ABC with activating ESR1 mutations for treatment with 99 fulvestrant. Prior clinical research suggests a fulvestrant dose response (15,16), and 100 patients were treated with extended dose fulvestrant (500mg) given every 2 weeks, 101 twice as frequent as standard dosing, to increase fulvestrant exposure and target 102 ESR1 mutant cancers. Median progression free survival was 2.2 months (17). Here 103 we investigate the genomic associations of response and resistance to fulvestrant in 104 Cohort A of the plasmaMATCH trial. We demonstrate that baseline ESR1 variants are 105 predictive of response to fulvestrant, with frequent acquisition of potentially targetable 106 mutations. We identify mutations at F404 in estrogen receptor, that occur in *cis* with 107 classical activating ESR1 mutations, and are acquired as a mechanism of resistance 108 to fulvestrant, identifying the first mechanism of acquired resistance specific to 109 fulvestrant.

# 111 Results

# 112 Baseline ESR1 variants and differential fulvestrant activity

113 Of the 84 patients enrolled onto Cohort A treated with extended dose fulvestrant, 79 114 (94%) had targeted sequencing results available for analysis, all of whom had 115 detectable ctDNA. The observed baseline mutations reflected the profile of aromatase 116 inhibitor pre-treated advanced breast cancer. Mutations in ESR1 (96%, 76/79 117 patients), PIK3CA (43% 34/79 patients) and TP53 (30% 24/79 patients) were the most 118 commonly identified at baseline (Figure 1A). Median PFS in patients with neither 119 PIK3CA nor TP53 mutations was not significantly altered (Supplementary Figure 1A 120 and B). The most frequent activating ESR1 alterations in the Cohort were D538G (n = 121 44, 55.7%), Y537S (n = 34, 43.0%), E380Q (n = 22, 27.9%), Y537N (n = 22, 27.9%), 122 Y537C (n = 11, 13.9%), L536R (n = 7, 8.9%) and S463P (n = 4, 5.1%; Figure 1B). We 123 assessed the impact baseline *ESR1* mutations had on fulvestrant efficacy. Patients 124 with detectable baseline Y537C alterations had longer median progression-free 125 survival (PFS) on fulvestrant compared to patients with other baseline ESR1 mutations 126 (5.6 month detected versus 2.0 months not detected, HR 2.8 [95% CI 1.3 to 5.9]; 127 Figure 1C *left* panel). Conversely, patients with a baseline Y537S mutation had shorter 128 median PFS (1.8 detected versus 3.5 months not-detected, HR 0.53 (95% CI 0.33 to 129 0.86; Figure 1C right panel). Median PFS in patients on fulvestrant with a baseline 130 D538G, E380Q, and Y537N mutations was not significantly different compared to 131 patients with other baseline *ESR1* mutations (Supplementary Figure 1C-E). To assess 132 the impact of common activating mutations on fulvestrant activity in vitro, we 133 conducted a screen of MCF7 cells with transient transfection of mutant ESR1 134 expression constructs, assessing the impact of mutations on fulvestrant activity on an 135 ERE reporter construct. Matching the clinical observations, Y537S induced a high level of resistance to fulvestrant, whilst Y537C was more sensitive (Figure 1D). This provides further evidence for fulvestrant resistance of Y537S mutations, adding to the prior data *in vitro* and *in vivo* (11,18-20), and clinical trial data (21).

# 139 Acquired mutations on fulvestrant.

140 Progression plasma DNA was sequenced in 70 patients, of whom 69 had a baseline 141 plasma sequenced (69/84, 82% enrolled patients). Pathogenic alterations were 142 acquired in 51% patients (35/69), particularly within estrogen and PI3K/AKT signalling 143 pathways (Figure 2A and Supplementary Figure 1F), including 17/69 (25%) patients 144 who acquired potentially targetable alterations, in genes including PTEN, BRCA1/2, 145 *PIK3CA, HER2* and *BRAF* (Figure 2A). The total number of acquired alterations was 146 not different in patients who gained clinical benefit (PR/SD >=24 weeks) versus those 147 that did not (Supplementary Figure 1G). For *ESR1* mutations, the majority of patients 148 (n = 50, 72.5%) maintained their respective poly- or monoclonal *ESR1* mutations, with 149 5.8% (n = 4) acquiring polyclonal disease through the course of treatment. In all 14/69 150 (20%) patients acquired ESR1 mutations at progression, including with 6/69 (9%) 151 patients who acquired L536 mutations. This matched the result of our ESR1 activation 152 mutation ERE screen, in which L536 mutations were the most resistant to fulvestrant 153 (Figure 1D), likely suggesting that L536 clones were selected through treatment due 154 to fulvestrant resistance.

# 155 Identification and investigation of ESR1 F404, a novel acquired mutation.

We noted that 3/69 (4%) patients acquired mutations at F404 on progression (Figure 2B), a mutation that had not previously been described amongst *ESR1* mutations, including one patient with five separate F404 mutations. The F404 locus is situated within the LBD of *ESR1*, with codon TTT encoding the phenylalanine (Figure 2C). All three patients had either a partial response or stable disease as their best response on fulvestrant. Of the patients with PFS ≥16 weeks, 12% acquired F404 mutations.
We additionally identified H356Y mutations in 3/69 (4%) patients, all in patients with
an activating L536P mutation, although subsequent functional experiments suggested
H356Y mutation did not impact ERα function (Supplementary Figure 2A and 2B).

165 All 3 of the patients with acquired F404 mutations harboured activating ESR1 E380Q 166 mutations at baseline, whilst two of the patients also had baseline D538G mutations. 167 *Cis/trans* analysis of the three patients with co-mutant E380Q (a loci close enough to 168 F404 to be able to establish *cis/trans* patterns in ctDNA) revealed that 6/7 F404 base 169 changes detected in these patients occurred in *cis* with the E380Q mutation (Figure 170 2D; Supplementary Figure 3). The patient with the mutation in *trans* with E380Q had additional ESR1 mutations (D538G, S463P and Y537N), and it is possible that the 171 172 F404 mutation was in *cis* with one of those mutations.

173 In the absence of prior fulvestrant exposure F404 mutations were very rare. Only 1/800 174 (0.1%) screening plasma samples from the plasmaMATCH study had an F404 175 mutation, and this one patient had previously received fulvestrant and had activating 176 mutations in ESR1 at D538G, E380Q, S463P and Y537N. Furthermore, we 177 interrogated other ctDNA data sets. In the PIPA combination study of fulvestrant, 178 palbociclib and taselisib, 1/16 (6%) patients acquired an F404 mutation at progression 179 (22). In the SERENA-1 study of the novel SERD camizestrant, baseline F404 180 mutations were identified in 2/214 (1%) patients both of whom had had prior fulvestrant 181 exposure and had other activating ESR1 mutations(23). Therefore, F404 mutations 182 were found only with prior fulvestrant exposure, only in combination with other 183 classical activating ESR1 mutations, and occurred in cis with activating mutations 184 expected to result in a translated protein that would carry the compound amino acid 185 changes.

186 The F404 amino acid residue contains an aromatic ring that, when estrogen is bound 187 to the receptor, forms a *pi*-stacking bond with a corresponding aromatic ring within 188 estrogen. Within the patients who harboured a F404 alteration, all base changes lead 189 to substitution of phenylalanine with one of either isoleucine, valine, or leucine, all of 190 which lack an aromatic ring (Figure 2E). Fulvestrant has a similar structure to estrogen 191 and includes an aromatic ring that forms a *pi*-staking bond with F404 in structural 192 modelling (Figure 2F). In silico analysis of binding energies (Supplementary Methods), 193 on mutant ESR1 backgrounds (Y537S or L536S), suggested mutations at F404 194 reduced the binding affinity of estrogen and fulvestrant to the estrogen receptor 195 (Supplementary Table 1). This potentially explains the clinical observation that F404 196 mutations only occurred in the presence of other activating *ESR1* mutations, as F404 197 mutation might otherwise impair estrogen binding and receptor activation in a wild-198 type ERa receptor.

# 199 <u>Generation and validation of ESR1 F404L models</u>

We investigated the functional consequences of F404 alteration, and the potential role in fulvestrant resistance, using both CRISPR knock in models and transfection of expression constructs. For both approaches, *ESR1* 1210T>C (F404L), one of the most frequently identified F404 variants, was modelled as a single mutation (F404L) or as a compound mutation in *cis* alongside activating *ESR1* mutations, D538G (1613A>G) and E380Q (1138G>C) selected for investigation as the most frequently co-occurring mutations in the clinical dataset.

207 MCF7 cells were subjected to CRISPR-Cas9 with homology directed repair (HDR) to 208 "Knock In" the target mutations. Clones were screened by Sanger sequencing of 209 genomic DNA. Any clones identified to harbour the targeted mutations were expanded 210 and expression of the mutant transcript confirmed by RT-PCR and Sanger sequencing

211 (Figure 3A). 3/72 (4%) F404 clones harboured the mutation, of which only 1/3 (33%; 212 F404L D10) was found to express F404L. 3/59 (5%) D538G clones harboured the 213 mutation, all which 3/3 (100%) expressed the mutant protein. One of D538G clones, 214 D538G D6C was noted to be homozygous for the mutation providing an ideal 215 background into which to knock in the p.F404L (Figure 3A). A second round of 216 CRISPR was used to introduce F404L into the D538G D6C model, with cells divided 217 into pools and subjected to estrogen free conditions without (E) and with (EF) 218 fulvestrant (0.5µM). 4/24 (17%) clones selected in the absence of estrogen (E) had 219 expression of F404L (Figure 3A). In contrast, 28/30 (93%) of clones selected with 220 fulvestrant (EF) had expression of F404L, providing clear evidence of preferential 221 selection.

222 Growth of both the parental MCF7 and F404L D10 cells was estrogen dependent. In 223 contrast, all models expressing D538G, and compound D538G+F404L, exhibited 224 estrogen independent growth (Figure 3B and 3C). Similarly, D538G expressing 225 models showed estradiol independent expression of the estrogen target gene 226 progesterone receptor (PgR) and trefoil factor1 (TFF1; Figure 3D), whereas F404L 227 showed estradiol dependent expression. Using an ERE-luciferase reporter gene 228 construct and transient expression, we further assessed the impact of F404L and 229 compound F404L+D538G mutations on estrogen mediated signalling (Figure 3E). 230 Cells transfected with D538G tended to increase ERE activity in the absence of 231 estrogen compared to cells expressing wild type ESR1 (Figure 3F). Notably, cells 232 expressing F404L showed lower ERE activity compared to cells expressing wild type 233 ESR1 when exposed to estrogen (P=0.0488, n=4; Figure 3F). Similarly, the 234 combination of E380Q, a less potent activator of ER signalling than D538G, and F404L 235 reduced ERE activity compared to wild type ESR1 (P<0.023, n=4). Together these

results are consistent with the hypothesis that F404L impacts the LBD of ERα, withoutactivating the receptor.

238

# 239 Compound F404 mutations and resistance to fulvestrant

240 We explored the impact of F404L on sensitivity of MCF7 cells to fulvestrant. CRISPR 241 models expressing F404L had modestly reduced in sensitivity to fulvestrant compared 242 to parental MCF7 cells in both short- and long-term assays (Figure 4A, 4B and 4C). Resistance to fulvestrant was substantially more marked in compound D538G+F404L 243 244 models showing profound resistance (Figure 4A and 4B). Similarly, quantification of 245 long-term colony formation assays show the compound D538G+F404L models clear 246 resistance to fulvestrant (Figure 4C). Single mutant CRISPR F404L, D538G models 247 and parental MCF7 cells had decreased expression of PgR, TFF1 and ERa when 248 treated with fulvestrant (Figure 4D). In contrast, models with compound D538G+F404L 249 had limited changes in expression of PgR, TFF1 and ERα when treated with 250 fulvestrant (Figure 4D). Supporting these observations, ERE activity associated with 251 transient expression of single and compound ESR1 variants was reduced by treatment 252 with fulvestrant, with the exception of D538G+F404L which maintained ERE activity 253 compared to cells treated with estradiol alone (Figure 4E). Consistent with this, the 254 combination of F404L+L536P, a combination not seen in the clinical dataset, 255 maintained ERE activity when treated with fulvestrant (Supplementary Figure 3). 256 Together this data confirms that the combined effect of compound F404 and activating 257 ESR1 mutations in *cis* in the same protein caused profound fulvestrant resistance.

# 258 <u>Compound F404 mutations increase estrogen dependent gene expression.</u>

259 To extend the observations of increased estrogen signalling in F404 compound 260 models treated with fulvestrant (Figures 3C and 4C), RNAseq was performed for 261 models grown in estradiol (1nM) with and without fulvestrant (1 $\mu$ M) for 24 hours (n=3). 262 Gene set enrichment analysis (GSEA) of D538G+F404L compound mutant models 263 grown with estrogen had decreased "Early estrogen pathway" expression but were 264 otherwise similar to D538G mutant cells (Figure 5A, FDR adjusted g<0.05;). However, 265 when treated with fulvestrant for 24hr, E2F transcription, MYC, proliferation and 266 estrogen mediated signalling were all significantly increased in the compound mutant 267 model (Figure 5B, FDR adjusted q<0.05;). The F404L-D10 model had significant 268 upregulation of estrogen signalling compared to the wildtype control (FDR adjusted 269 q<0.05). Similarly, estrogen signalling was increased in the D538G-D6C model 270 compared to the wildtype control maintained with and without fulvestrant treatment 271 (FDR adjusted q<0.05; Figure 5C). Addition of F404L to D538G (D358G+F404L EF 272 models), showed significant activation of both E2F target and estrogen response (early 273 and late) pathways with fulvestrant treatment (FDR adjusted q<0.05; Figure 5C). 274 Differential response of the late estrogen response genes illustrated in Figures 5D 275 (estradiol; Supplementary Figure 4A) and 5E (Fulvestrant; Supplementary Figure 4B).

We noted two observations that suggested *ESR1* F404 mutations might be deleterious in the absence of fulvestrant. F404 Compound mutations had lower "Early estrogen pathway" expression (Figure 5A), and introduction of F404 reduced ERE activity compared to wildtype protein in the presence of estrogen (Figure 3E). Consistent with this the three double mutants expressing F404L models that were selected in the presence of estrogen "E" (Figure 3A), all lost the F404L mutation in long term growth (Supplementary Figure 5), likely suggesting a subclonal mutation that was

283 outcompeted by the F404F wildtype clone in long-term growth in the absence of284 fulvestrant.

#### 285 <u>Compound F404 mutations are sensitive to novel SERDs.</u>

286 In silico analysis of binding energies suggested mutations at F404L may increase the 287 binding affinity of second-generation oral SERDs (Supplementary Table 1). Therefore, 288 we investigated if fulvestrant resistance generated through compound F404 mutations 289 could be overcome by novel SERDs in clinical development, or by the selective 290 estrogen receptor modulator (SERM) tamoxifen. All novel SERDS investigated were 291 active against CRISPR models with both single F404L mutations and D538G+F404L 292 compound mutations, including elacestrant, camizestrant, 4OH tamoxifen and 293 giredestrant (Figure 6A-E, Table 1; Supplementary Figures 6-9). In particular, models 294 with D538G+F404L compound mutations that were overtly resistant to fulvestrant, 295 showed sensitivity to other SERD/SERMs comparable to other D538G expressing 296 (Figure 6A-E; Supplementary Figures 6-9). Similarly, models elacestrant. 297 camizestrant, 40H tamoxifen or giredestrant all fully inhibited ERE activity following 298 transient transfection of D538G+F404L and E380Q+F404L (Figure 6F), despite 299 transfection of these compound mutations resulting in substantial resistance to 300 fulvestrant. Interestingly, 4OH tamoxifen did not completely suppress activity of the 301 ERE reporter gene assay, with ~10-20% activity irrespective of ESR1 mutation (Figure 302 6F), potentially reflecting the difference in mechanism of action between it and the 303 SERDs.

#### 304 Discussion

305 Here, we present a robust genomic analysis of resistance to fulvestrant in ESR1 306 mutant breast cancer using paired circulating tumour DNA sequencing in patients 307 treated with fulvestrant in the plasmaMATCH study(17). We identify novel ESR1 308 mutations that alter F404, that occur only in patients treated with fulvestrant with pre-309 existing activating ESR1 mutations in their cancer. F404 mutations are acquired in cis 310 with a pre-existing activating *ESR1* mutation, with the resulting compound mutation 311 resulting in profound resistance to fulvestrant, but with retained sensitivity to a range 312 of novel SERDs, identifying a treatment strategy to overcome acquired resistance 313 conveyed by F404 mutations.

314 Mutations at F404 do not appear to occur in the absence of fulvestrant exposure, and 315 then also only in the presence of other activating *ESR1* mutations. F404 has previously 316 been predicted to form *pi*-stacking bonds with plant polyphenols identified in a screen 317 of compounds as candidates with anti-estrogenic properties (24). Similarly, structural 318 analysis suggested that F404 forms a *pi*-stacking bond with an aromatic ring in both 319 estradiol and fulvestrant. Consistent with these predictions, in vitro, the introduction of 320 F404 mutations resulted in lower levels of ERE activity compared to wildtype ESR1 321 (Figure 3). Mutation of F404 would likely reduce *ESR1* activity in the absence of other 322 ESR1 mutations, which may have a deleterious effect on tumour growth, explaining 323 the lack of F404 mutations observed without prior acquisition of an activating ESR1 324 mutation. Compound F404 mutations resulted in profound resistance to fulvestrant, 325 with single F404 mutant models showing more limited fulvestrant resistance. It is likely 326 that the effect of *ESR1* activating mutations on the ligand binding pocket, combined 327 with the loss of the *pi*-stacking bond, result in an impairment of fulvestrant affinity for

328 the ligand binding pocket. In silico analysis of binding energies was consistent with 329 this hypothesis, although formal *in vitro* studies in the future would be required to 330 assess this (Supplementary Table 1), with the alternative hypothesis being that F404X 331 mutations do not impact the binding of fulvestrant, but impact the conformational 332 change induced by fulvestrant binding. Interesting in silico analysis predicted that 333 binding energies of novel SERDs were not affected by, or even promoted by, F404 334 mutations, and consistent with this the efficacy of novel SERDs, was unaffected by 335 mutations in F404, providing a therapeutic option to circumvent this mechanism of 336 resistance. Investigation of a wider range of SERDs/SERMs is required to confirm 337 whether this resistance mutation is, as is currently suggested, specific to fulvestrant. 338 This endocrine therapy resistance mechanism is unique in leading to re-activation of 339 the estrogen receptor itself, in contrast to other mechanisms such as inactivating NF1 340 and ARID1A mutations (25,26), emphasising the need to identify whether further drug 341 specific mutations may limit the efficacy of oral ER degraders in clinical development.

342 Interestingly, our results predict that although F404 compound mutations promote 343 growth in the presence of fulvestrant, this conditional advantage may come at the 344 come at the cost of reduced fitness in the absence of fulvestrant, as F404 mutations 345 may reduce ER signalling in the absence of fulvestrant and therefore come at the cost 346 of impaired clonal growth once fulvestrant is withdrawn (Supplementary Figure 5). This 347 suggests that for patients with resistance to fulvestrant generated by F404 mutations, 348 there may be the possibility of rechallenging with fulvestrant after a treatment break, 349 as has been seen rechallenging with cetuximab in patients who KRAS mutations in 350 colorectal cancer(27).

351 Our study emphasises the extent to which tumour genomes may evolve through 352 fulvestrant therapy, with 25% patients acquiring a potentially targetable driver 353 mutation. Evidence suggests that ER positive breast cancers may become 354 substantially heterogeneous after progression on endocrine therapy, and that 355 heterogeneity presents a considerable challenge to subsequent treatment efficacy 356 (21,28,29). The high incidence of mutation 'acquisition' was largely driven by gain of 357 ESR1 mutations, and likely reflects clonal selection in the cancer, whilst emphasising 358 the importance of ctDNA liquid biopsy testing to match treatment to current genomics 359 (17). This heterogeneity may be more marked in *ESR1* mutant cancer, as *ESR1* 360 mutations may co-occur with other mechanisms of genetic resistance, potentially 361 reflecting cancers that are pre-disposed to acquiring genetic mechanisms of 362 resistance (21,29) Recently, acquisition of secondary mutations in *cis* with hotspot 363 driver mutations in *PIK3CA* were described (30), leading to increased signalling and 364 tumour growth. PIK3CA double mutants were found to have increased sensitivity to 365 PI3K inhibitors (30). Similarly, we report double mutations in *ESR1* where the primary 366 mutation has been widely described (11,19,21,29,31), acquired in response to 367 exposure to aromatase inhibitors (7). In contrast to *PIK3CA* double mutations which 368 enhance PI3K signalling, acquisition of F404 only provides a growth advantage in the 369 context of exposure to fulvestrant.

In conclusion, we identify a novel *ESR1* mutation at ER $\alpha$  F404, that when acquired in combination with an activating *ESR1* mutation induces resistance to the widely used SERD fulvestrant. Mutations at this codon result in changes at F404 to amino acid residues which lack an aromatic ring, disrupting the *pi*-stacking bond with both estradiol and fulvestrant. The resistance of F404 double mutants is specific to fulvestrant and can be overcome by use of alternate SERDs, suggesting a route to overcome therapeutic resistance in the clinic. Mutations in the estrogen receptor can

- 377 confer resistance to ER binding drugs, without promoting ER activity, identifying a new
- 378 mechanism through which the cancer can become resistant to hormonal therapies.

#### 380 Materials and Methods

# 381 Patient enrolment into plasmaMATCH and blood sampling

382 The plasmaMATCH trial (NCT03182634), was co-sponsored by the Institute of Cancer 383 Research and the Royal Marsden National Health Service (NHS) Foundation Trust. 384 London, UK, and approved by a Research Ethics Committee (16/SC/0271), as 385 previously reported (17). Baseline ctDNA testing was conducted with droplet digital 386 PCR (ddPCR), and from partway through the trial with targeted sequencing in parallel 387 to ddPCR. For patients enrolled prior to prospective targeted sequencing, a banked 388 pre-treatment plasma sample was retrospectively sequenced. An additional plasma 389 sample taken at disease progression was also subject to targeted sequencing.

390 For the baseline ctDNA test, 30-40ml of blood was collected in 3–4 10ml cell-free DNA 391 BCT Streck tubes. 30ml of blood was shipped at ambient temperature to a central 392 laboratory (Centre for Molecular Pathology, Royal Marsden Hospital) for ddPCR 393 testing and retrospective targeted sequencing. In addition, from partway through the 394 trial 10ml blood were shipped to Guardant Health (Redwood City, California, USA) for 395 targeted sequencing. An additional sample was collected at cycle 1 day1, and end of 396 treatment sample in 2 x 10mL BD Vacutainer® EDTA tubes, centrifuged within 1 hour 397 of collection, for retrospective targeted sequencing.

# 398 <u>Computer modeling of estrogen *pi*-stacking with ER</u>

Models of estrogen ligand A-ring *pi*-stacking with F404 in the ligand binding pocket of ER $\alpha$  were generated as follows: There is no crystal structure for fulvestrant bound to ER $\alpha$ ; the only related crystal structure is for ICI 164,384, a close fulvestrant analog, in the other ER subtype, ER $\beta$  (PDB ID 1HJ1). Therefore, we removed the ICI 164,384 ligand from this structure, modified the side chain to match that of fulvestrant, and

404 modelled it into the ERα crystal structure for the antiestrogen Bazedoxifene after
405 removing the Bazedoxifene ligand (PDB ID 6PSJ); the fitting was done using
406 Schrödinger Glide (https://www.schrodinger.com/products/glide). The estradiol
407 structure in ERα is from PDB ID 3UUD.

#### 408 ctDNA testing and analysis.

409 ctDNA targeted sequencing was conducted with Guardant360 that identifies single
410 nucleotide variants (SNVs), indels, copy number alterations and fusions within protein411 coding regions of 73 (version 2.10) or 74 genes (version 2.11), as previously
412 described(29,32).

413 Variants from Guardant 360 were annotated with VEP version 96(33). Germline calls 414 were identified by Guardant360 with additional calls (identified based on a combination 415 of VAF frequency around 50%+- 2% and VAF in general population in the Genome 416 Aggregation Database >0.001%) excluded. To identify pathogenic mutations, variants 417 were annotated with OncoKB(34) and CancerHotspots(35). Mutations were classified 418 as pathogenic based on Cancer Hotspots or OncoKB annotations or recurrent 419 mutations in key breast cancer genes (ESR1, HER2, PIK3CA, EGFR, RB1 and 420 FGFR2) or splicing mutations. All analyses presented are based on mutations 421 assessed as likely pathogenic. Targetability was assigned using OncoKB annotation, 422 a manually curated database of alterations(34).

# 423 Cell Lines

424 MCF7 cell lines were obtained from ATCC and cultured in phenol free RPMI media 425 (32404-014, Life technologies) supplemented with 10% dextran/charcoal stripped FBS 426 (12676029, Life Technologies), 1nM oestradiol (Sigma), glutamine (25030149, Life 427 technologies), penicillin and streptomycin (15140-122, Life technologies). Cell lines

were banked in multiple aliquots on receipt to reduce risk of phenotypic drift and
identity confirmed by STR profiling with the PowerPlex 1.2 System (Promega). Cell
cultures were routinely tested for presence of mycoplasma using MycoAlert®
Detection kit (LT07-318 Lonza).

# 432 Antibodies and Drugs

Antibodies used were ERα (sc543, Santa Cruz Biotechnology), PGR (8757, Cell
Signaling Technology), TFF1 (15571, Cell Signaling Technology) and βactin (A5441
Sigma). Secondary antibodies used were α-rabbit-HRP (7074) and α-mouse-HRP
(7076, Cell Signaling Technology). Fulvestrant (S1191), 4OH-tamoxifen (S7827) and
camizestrant (S8958) were obtained from Selleck Chemicals. Elacestrant (HY19822A) and giredestrant (HY-109176) were obtained from MedChemExpress.

# 439 <u>Generation and analysis of ESR1 mutant CRISPR models</u>

440 MCF7 cells were subjected to CRISPR-Cas9 genome editing with homology-directed 441 repair (HDR) using Integrated DNA Technologies' (IDT) Alt-R<sup>™</sup> CRISPR-Cas9 system 442 according to manufacturer's guidelines. Briefly, the day before transfection 250,000 443 cells were plated per well of a 6 well plate in antibiotic free media containing HDR 444 enhancer V2 (2µM, 10007910 IDT). crRNA and HDR templates were designed using 445 IDT's Alt-R™ CRISPR HRD design tool (https://eu.idtdna.com/pages/tools/alt-r-crispr-hdr-446 design-tool; Supplementary table 2). gRNA complexes (1µM) were prepared by 447 hybridisation of targeting crRNA with tracrRNA-ATTO555 (1075928, IDT). 448 Ribonucleoprotein (RNP) complexes were prepared by addition of gRNA complexes, 449 Cas9 (1081060 IDT), HDR template, Cas9 PLUS reagent (ThermoFisher Scientific), 450 and OptiMEM (31985062, ThermoFisher Scientific), and incubated for 5min at room 451 temperature. Transfection mixes were prepared using RNP complexes with Lipofectamine<sup>™</sup> CRISPMAX<sup>™</sup> (CMAX00008, ThermoFisher Scientific) and incubated 452

453 for 20mins at room temperature. Transfection mixes were added to pre-seeded cells 454 in 6 well plates and incubated overnight. 48h post transfection cells were spilt into 455 10cm dishes and cells cultured until colonies had established. gDNA was extracted 456 from the transfection pool using QuickExtract<sup>™</sup> DNA Extraction Solution (QE09050 457 Lucigen) and CRISPR editing assessed using Alt-R Genome Editing Detection kit 458 (1075932 IDT). After approximately 2 weeks individual colonies were picked into 96 459 well plates and expanded. gDNA was extracted from colonies using QuickExtract™ 460 DNA Extraction Solution (QE09050 Lucigen), subjected to PCR (primer details in 461 Supplementary table 1), PCR products isolated (QIAquick PCR purification kit, 28104 462 Qiagen) and screened for presence of targeted mutations by Sanger sequencing 463 (Azenta Life Sciences). Clones in which targeted mutations were identified were 464 expanded.

To confirm mutant *ESR1* variants were expressed by selected clones, RNA was extracted using RNeasy Mini Kit (74104, Qiagen), cDNA prepared using SuperScript IV first strand synthesis kit (18091050, ThermoFisher Scientific) and amplified using AllTaq PCR Core Kit (203123, Qiagen; primer details in Supplementary table 1). As described, PCR products were isolated and screened for presence of targeted mutations by Sanger sequencing (Azenta Life Sciences).

# 471 Fulvestrant Screen of ESR1 mutant expressing MCF7 cells

472 A series of expression constructs with *ESR1* point mutations was generated in the 473 pcDNA3.1 HA-ERα (18). Transfections of MCF7 cells using HA-tagged wild-type or 474 mutant ERα, with 3×-ERE-TATA-Luciferase reporter and pRL-TK-Renilla luciferase 475 plasmid (Promega) using Lipofectamine 2000 (Life technologies) were done according 476 to the methods of Toy et al 2013 (18). Cells were exposed to fulvestrant at indicated 477 concentrations 1 day after transfection for 24h, and luciferase activities were

determined using the Dual® Luciferase Reporter Assay System (E2920, Promega)
according to the manufacturer's instructions. Luciferase bioluminescence
measurements were performed with the Veritas Microplate Luminometer (Promega).

# 481 ERE assays with transient transfection

482 pcDNA3.1+/C-DYK plasmids, with the open reading frame of ESR1 (NM 000125.4) 483 with and without point mutations (estrogen receptor constructs, ERCs; Supplementary 484 Table 2), were purchased from GenScript (The Netherlands). Sanger sequencing was 485 used to confirm the presence of the desired mutations within the custom insert. MCF-486 7 cells were seeded in 6 well plates with 250,000 cells per well in antibiotic free media, 487 the following day transfected using Fugene 6 (Promega, USA) with the ERC, a plasmid 488 expressing an estrogen response element with firefly luciferase (ERE-luciferase) (36) and pRL-CMV (Renilla luciferase control, Promega). 24 hours post transfection, 489 490 experimental conditions were applied for a further 24h, and firefly luciferase (ERE 491 activity) and Renilla luciferase using the Dual-Glo® Luciferase Assay System (E2920, 492 Promega) following the manufacturer's instructions measured with a VICTOR X3 493 MultiLab. Experiments were repeated a minimum of 3 times.

# 494 In Vitro Viability Assessment

495 Colony formation assays were conducted in 6-well plates, seeded with 10,000 496 cells/well prior to exposure to the indicated experimental conditions. Plates were fixed 497 with tricyclic acid (10%<sup>v</sup>/<sub>v</sub>), stained with sulforhodamine B (S1402, Sigma; 0.37% <sup>w</sup>/<sub>v</sub>, 498 in 1% acetic acid) and colonies counted using a GelCOUNT instrument (Oxford 499 Technologies). For short-term survival assays, 700cells/well were plated in 384 well 500 plates and exposed to indicated drugs. Survival was assessed after 6 days of 501 treatment using CellTiter-Glo cell viability assay (G7572, Promega).

# 502 Western Blotting

503 Cells were lysed in NP40 lysis buffer (1% v/v NP40, 10 mmol/L Tris-Cl pH8, 150 504 EDTA, 1 mmol/L DTT) mmol/L NaCl, 1 mmol/L supplemented with 505 protease/phosphatase inhibitor cocktail (5872, Cell Signaling Technologies). Western 506 blots were carried out with precast Bis-Tris gels (Life Technologies).

# 507 <u>RNAseq expression analysis</u>

*ESR1* mutant models and controls were treated with 1nM estradiol ± 1µM fulvestrant
for 24hr (9 models with estradiol treatment, 7 of which also had fulvestrant treatment,
n=3), cells harvested, and RNA extracted using RNeasy Mini Kit (74104, Qiagen).
Each cell model was treated in 3 independent experiments.

512 48 total RNA samples were sent to Novogene (UK) Company Ltd and subjected to 513 Eukaryotic mRNA-Seq (Illumina Novaseq PE150, Q30 ≥ 80%). Sequencing data for 514 48 RNA samples for 9 models using bcbio-nextgen, 1.2.4 pipeline, reads were aligned 515 using STAR with version STAR 2.6.1d, counted using salmon, 1.4.0. The data was 516 divided in two parts with respect to treatment with 1nM estradiol and 1µM fulvestrant 517 as EST and FUL. The data normalized using DEseq2 version '1.38.3'. DESeq2 was 518 also used to determine differentially expressed genes between different model of 519 single mutants (404 D10, 538 D6C) versus control (MCF7), single mutants 520 (404 D10, 538 D6C) versus wt D11 and double mutants (538 404, 404 538) vs 521 single mutants (538 D6C, 404 D10) using shrunken log2 fold changes in EST and 522 FUL data respectively. Heatmaps were generated using pheatmap package version 523 '1.0.12' and ggplots '3.4.2' R package. GSEA analysis was carried out using Molecular 524 Signatures Database 'Hallmarks' gene set collection using package fgsea '1.24.0' and 525 clusterProfiler '4.6.2' R packages.

526 <u>Statistical analyses</u>

527 Statistical analysis was carried out using R version 4.0.5 and GraphPad Prism v8.4.3. 528 Time to event survival data were analysed with log-rank test and hazard ratios were 529 calculated with Cox regression. Plots were created using GraphPad Prism v8.4.3 and 530 the R software packages ggplot2 and survminer.

531

# 532 Data Availability Statement

533 The processed plasmaMATCH Guardant360 sequencing data generated and 534 analysed during the current study are available as part of Kingston B, et al 2021 (29). 535 We do not have permission from the patients to publicly deposit the raw sequencing 536 data. To protect the privacy and confidentiality of patients in this study, clinical data 537 are also not made publicly available. The data can be obtained by submitting a formal 538 data access request in accordance with the Institute of Cancer Research Clinical Trials 539 and Statistics Unit (ICR-CTSU) data and sample access policy. Requests are to be 540 made via a standard proforma describing the nature of the proposed research and 541 extent of data requirements which is reviewed by the trial management group. Data 542 recipients are required to enter a formal data sharing agreement, which describes the 543 conditions for data release and requirements for data transfer, storage, archiving, 544 publication, and intellectual property. Trial documentation including the protocol are 545 available on request by contacting plasmamatch-icrctsu@icr.ac.uk.

546

# 547 Acknowledgments

548 This research was funded by Cancer Research UK and Breast Cancer Now, and 549 sequencing of ctDNA was conducted by Guardant Health. The plasmaMATCH trial is funded by Cancer Research UK (CRUK/15/010, C30746/A19505), with additional 550 551 support from AstraZeneca, Puma Biotechnology, Guardant Health and BioRad. 552 Grateful thanks to all trial participants and their families. We thank Breast Cancer Now 553 for funding this work as part of Programme Funding to the Breast Cancer Now Toby 554 Robins Research Centre. This study represents independent research supported by 555 the NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust 556 and the Institute of Cancer Research, London. 557 This study was presented in part at the 2022 American Society of Clinical Oncology

558 3-7th June 2022, J Clin Oncol 40, 2022 (suppl 16; abstr 1009), 559 https://doi.org/10.1200/JCO.2022.40.16 suppl.1009.

560

# 561 References

- 5621.Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in563Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med564**2015**;373(3):209-19 doi 10.1056/NEJMoa1505270.
- 5652.Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al.566Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast567Cancer. N Engl J Med **2019**;380(20):1929-40 doi 10.1056/NEJMoa1813904.
- Sledge GW, Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, *et al.* The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone ReceptorPositive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol
  2020;6(1):116-24 doi 10.1001/jamaoncol.2019.4782.
- 573 4. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor 574 antagonist with a novel mechanism of action. Br J Cancer **2004**;90 Suppl 1:S2-575 6 doi 10.1038/sj.bjc.6601629.
- 576 5. Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, Greene GL, 577 Chandarlapaty S. Structural underpinnings of oestrogen receptor mutations in

578 endocrine therapy resistance. Nat Rev Cancer **2018**;18(6):377-88 doi 10.1038/s41568-018-0001-z.

- 580 6. Guan J, Zhou W, Hafner M, Blake RA, Chalouni C, Chen IP, *et al.* Therapeutic
  581 Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. Cell
  582 2019;178(4):949-63 e18 doi 10.1016/j.cell.2019.06.026.
- 583 7. Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et 584 al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution 585 metastatic breast Sci durina therapy for cancer. Transl Med 586 2015;7(313):313ra182 doi 10.1126/scitranslmed.aac7551.
- 587 8. Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, et al.
  588 Heterogeneity and clinical significance of ESR1 mutations in ER-positive 589 metastatic breast cancer patients receiving fulvestrant. Nat Commun 590 2016;7:11579 doi 10.1038/ncomms11579.
- 591 9. Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, et al.
  592 ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in
  593 Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of
  594 the Phase III SoFEA and EFECT Trials. Clin Cancer Res 2020;26(19):5172-7
  595 doi 10.1158/1078-0432.CCR-20-0224.
- Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, *et al.*ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. Clinical Cancer Research 2020;26(19):5172-7 doi 10.1158/1078-0432.Ccr-20-0224.
- Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, *et al.*Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
  Cancer Discov **2017**;7(3):277-87 doi 10.1158/2159-8290.CD-15-1523.
- Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, *et al.* Elacestrant
  (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor
  Activity in Multiple ER(+) Breast Cancer Patient-derived Xenograft Models. Clin
  Cancer Res **2017**;23(16):4793-804 doi 10.1158/1078-0432.CCR-16-2561.
- 608 Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasguale AG, et al. GDC-13. 609 9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen 610 Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for 611 J ER+ Breast Cancer. Med Chem **2021**;64(16):11841-56 doi 612 10.1021/acs.jmedchem.1c00847.
- 613 14. Scott JS, Moss TA, Balazs A, Barlaam B, Breed J, Carbajo RJ, *et al.* Discovery
  614 of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor
  615 Degrader and Antagonist. J Med Chem 2020;63(23):14530-59 doi
  616 10.1021/acs.jmedchem.0c01163.
- bi Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, *et al.* Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized
  CONFIRM trial. J Natl Cancer Inst **2014**;106(1):djt337 doi 10.1093/jnci/djt337.
- Patani N, Dunbier AK, Anderson H, Ghazoui Z, Ribas R, Anderson E, et al.
  Differences in the transcriptional response to fulvestrant and estrogen
  deprivation in ER-positive breast cancer. Clin Cancer Res 2014;20(15):396273 doi 10.1158/1078-0432.CCR-13-1378.
- Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, *et al.* Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol **2020**;21(10):1296-308 doi 10.1016/S1470-2045(20)30444-7.

- Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, *et al.* ESR1 ligand-binding
  domain mutations in hormone-resistant breast cancer. Nat Genet **2013**;45(12):1439-45 doi 10.1038/ng.2822.
- Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, *et al.* Activating ESR1
  mutations in hormone-resistant metastatic breast cancer. Nat Genet **2013**;45(12):1446-51 doi 10.1038/ng.2823.
- Harrod A, Lai CF, Goldsbrough I, Simmons GM, Oppermans N, Santos DB, *et al.* Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer. Oncogene **2022**;41(44):4905-15 doi 10.1038/s41388-022-02483-8.
- O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, *et al.* The Genetic
  Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib
  plus Fulvestrant in the PALOMA-3 Trial. Cancer Discov 2018;8(11):1390-403
  doi 10.1158/2159-8290.CD-18-0264.
- Pascual J, Lim JSJ, Macpherson IR, Armstrong AC, Ring A, Okines AFC, *et al.*Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant
  Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid
  Cancers. Cancer Discov 2021;11(1):92-107 doi 10.1158/2159-8290.CD-200553.
- 647 23. Mafalda Oliveira EPH, Jason Incorvati, Begoña Bermejo de la Heras, Emiliano 648 Calvo, Javier García-Corbacho, Manuel Ruiz-Borrego, Christos Vaklavas, 649 Nicholas C. Turner, Eva M. Ciruelos, Manish R. Patel, Anne C. Armstrong, 650 Peter Kabos, Chris Twelves, Tim Brier, Itziar Irurzun-Arana, Teresa Klinowska, 651 Justin P.O. Lindemann, Christopher J. Morrow, Richard D. Baird. Serena-1: 652 Updated analyses from a phase 1 study (parts C/D) of the next-generation oral 653 SERD camizestrant (AZD9833) in combination with palbociclib, in women with 654 ER-positive, HER2-negative advanced breast cancer. Journal of Clinical 655 Oncology **2022**;40(16 suppl):1032 doi 10.1200/JCO.2022.40.16 suppl.1032.
- 4. Yugandhar P, Kumar KK, Neeraja P, Savithramma N. Isolation,
  characterization and in silico docking studies of synergistic estrogen receptor a
  anticancer polyphenols from Syzygium alternifolium (Wt.) Walp. J Intercult
  Ethnopharmacol 2017;6(3):296-310 doi 10.5455/jice.20170709031835.
- Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S, Papachristou EK, et *al.* ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and
  breast cancer treatment response. Nat Genet 2020;52(2):187-97 doi
  10.1038/s41588-019-0541-5.
- Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B, et *al.* Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and
  Contribute to Endocrine Therapy Resistance. Clin Cancer Res 2020;26(3):60822 doi 10.1158/1078-0432.CCR-18-4044.
- Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et *al.* Clonal evolution and resistance to EGFR blockade in the blood of colorectal
  cancer patients. Nat Med **2015**;21(7):795-801 doi 10.1038/nm.3870.
- Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, *et al.* The
  Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
  Cancer Cell **2018**;34(3):427-38 e6 doi 10.1016/j.ccell.2018.08.008.
- Kingston B, Cutts RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, *et al.*Genomic profile of advanced breast cancer in circulating tumour DNA. Nat
  Commun **2021**;12(1):2423 doi 10.1038/s41467-021-22605-2.


- Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, *et al.* Double
  PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kalpha
  inhibitors. Science **2019**;366(6466):714-23 doi 10.1126/science.aaw9032.
- 680 Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M. et al. 31. 681 Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive 682 Advanced Breast Cancer. J Clin Oncol **2016**;34(25):2961-8 doi 683 10.1200/JCO.2016.67.3061.
- Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, *et al.*Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay
  Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. Clin Cancer
  Res 2018;24(15):3539-49 doi 10.1158/1078-0432.CCR-17-3831.
- 68833.McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The689Ensembl Variant Effect Predictor. Genome Biol **2016**;17(1):122 doi69010.1186/s13059-016-0974-4.
- 691 34. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, *et al.* OncoKB:
  692 A Precision Oncology Knowledge Base. JCO Precis Oncol **2017**;1:1-16 doi
  693 10.1200/PO.17.00011.
- 694 35. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al.
  695 Identifying recurrent mutations in cancer reveals widespread lineage diversity
  696 and mutational specificity. Nat Biotechnol 2016;34(2):155-63 doi
  697 10.1038/nbt.3391.
- Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced
  estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways
  operate during the adaptation of MCF-7 cells to long term estrogen deprivation.
  J Biol Chem **2003**;278(33):30458-68 doi 10.1074/jbc.M305226200.
- 702 37. Zhou X, Edmonson MN, Wilkinson MR, Patel A, Wu G, Liu Y, *et al.* Exploring genomic alteration in pediatric cancer using ProteinPaint. Nat Genet 2016;48(1):4-6 doi 10.1038/ng.3466.

# **Table 1. Calculated IC50 and EC50 of 4OH tamoxifen and novel SERDs in ESR1 mutant models.**

		MCF7	WT D11	F404L D10	D538G D6C	404 538 1EF	538 404 30EF	538 404 34EF	538 404 36EF	538 404 37EF
Elacestrant	IC50 (nM)	12.2	3.9	5.4	27.7	20.1	23.3	34.6	nc	35.5
	EC50 (nM)	16.2	10.7	6.9	59.0	24.9	27.5	46.3	67.0	57.8
Camizestrant	IC50 (nM)	1.0	0.7	1.8	14.0	9.6	9.9	15.1	7.5	15.8
	EC50 (nM)	2.5	2.2	2.2	28.8	10.9	12.2	20.8	47.2	25.3
40H tamoxifen	IC50 (nM)	5.6	1.2	1.4	16.8	10.3	8.7	14.4	11.1	20.6
	EC50 (nM)	8.9	7.1	3.4	37.9	14.9	11.8	21.7	95.3	46.9
Giredestrant	IC50 (nM)	1.2	0.3	0.4	3.1	2.5	2.5	3.7	1.0	4.2
	EC50 (nM)	1.3	0.8	0.5	6.3	3.1	3.2	4.6	9.2	6.9

707 nc not calculated


#### Figures



# 712 Figure 1. Baseline *ESR1* mutations and fulvestrant efficacy

A. % Incidence of mutations in indicated genes at baseline in Cohort A (n=79assessable patients).

- 715 B. Incidence of baseline *ESR1* alterations within Cohort A (n=79 assessable patients).
- 716 C. Progression-free survival of patients in Cohort A, divided by baseline *ESR1* Y537C
- 717 mutation status (left) and *ESR1* Y537S mutation status (right). p-values from log rank
- test. HR >1 denotes worse PFS for that group. WT, wild type; mt, mutant
- D. MCF7 cells were co-transfected with the indicated *ESR1* expression constructs and
- treated with the indicated concentration of fulvestrant in the presence of 1nM estradiol
- for 24 hours and ERE-luciferase reporter activity determined. 2 independentexperiments.



# 726 Figure 2. Acquired mutations on Fulvestrant.

A. incidence of acquired alterations (n=69 assessable patients), coloured by targetability of the alterations (methods). Level 2B denotes the highest level of supporting evidence ("Standard care biomarker recommended by the NCCN or other professional advice guidelines predictive of response to an FDA-approved drug"), while Level 4 is the lowest ("Compelling biochemical evidence supports the biomarker as being predictive of response to a drug").

B. incidence of acquired *ESR1* mutations (n=14 patients), and resultant amino acidchanges.


C. *ESR1* F404 locus in the DNA-binding domain of the estrogen receptor. The number
of base changes identified within the dataset that result in the three different missense
mutations are illustrated using https://proteinpaint.stjude.org/ (37).

D. *cis/trans* analysis of F404 and E380Q in the three patients with assessable targeted
sequencing data. Both alleles of chromosome 6 are represented, with annotated
location of the F404 and E380Q on each respective allele representing the *cis/trans*relationship of the variants.

742 E, Mutations at phenylalanine 404 result in substitution of amino acid residues without743 an aromatic ring.

F, *In silico* modelling predicts the aromatic ring of F404 contributes to a *pi*-stacking
bond between the receptor and both estrogen and fulvestrant.

746



ESR1 Expression Construct

#### 748 Figure 3. F404 does not activate estrogen signalling.

A. CRISPR clones of MCF7 cells expressing *ESR1* F404L (1210T>C, CRISPR edit
indicated by red arrows) or D538G (1613A>G; CRISPR edit indicated by black arrows)
were identified by RT-PCR followed by Sanger sequencing (left hand panels).
Similarly, a second round of CRISPR was used to introduce *ESR1* F404L (1210T>C)
into a clone (D6C) that expressed D538G (1613A>G; right hand panels).

B. Estrogen dependent growth was assessed in colony formation assay. Parental
MCF7 cells and indicated *ESR1* mutant models were grown in either the absence or
presence of estradiol (1nM) for 14 days.


C. Quantification of colony formation assays of *ESR1* mutant models treated with and
without estradiol (1nM). SRB stained colonies were dissolved and absorbance at
565nm measured. Mean with sem, n=3 independent experiments, nonparametric one
way ANOVA with Dunn's multiple comparisons test, \*\*P<0.01.</li>

D. Expression of estrogen target genes, progesterone receptor (PgR) and trefoil factor-1 (TFF1), assessed by western blot in parental MCF7 cells and indicated *ESR1* mutant models grown in either the absence or presence of estradiol (1nM) for 24 hours.

765 E. MCF7 cells were transfected with *ESR1* expression constructs with indicated *ESR1*766 variants. Expression of ERα was determined by western blot.

F. MCF7 cells were co-transfected with the indicated *ESR1* expression constructs
ERE-luciferase reporter and control construct. Cells were treated in either the absence
or presence of estradiol (1nM) for 24 hours and ERE-luciferase activity assessed. 2-

- 770 way repeated measures ANOVA with Dunnett's multiple comparisons test, n=4 mean
- 771 with SD, \*P<0.05.



ESR1 Expression Construct

# 775 **Figure 4. Compound F404L mutations induces resistance to fulvestrant.**

A. Compound mutations of D538G-F404L in MCF7 cells, along with single mutations
and wildtype, with sensitivity to fulvestrant assessed after 6 days treatment with Cell
Titre Glo viability assay. N=4 mean with SD.


B. Representative images of clonongenic assays grown in indicated concentrations offulvestrant for 14 days.

C. Quantification of colony formation assays for *ESR1* mutant models treated with the indicated concentrations of fulvestrant for 14 days. EC50 and IC50 values were calculated from the response curves. SRB stained colonies were dissolved and absorbance at 565nm measured. Mean with sem, n=3 independent experiments.

D. Expression of estrogen target genes, progesterone receptor (PgR) and trefoil
factor-1 (TFF1), assessed by western blot in parental MCF7 cells and indicated *ESR1*mutant models grown in the presence of 1nM estradiol or 1µM fulvestrant.

E. MCF7 cells were co-transfected with the indicated *ESR1* expression constructs RE-luciferase reporter and control construct. Cells were treated with 1nM estradiol either the absence or presence of fulvestrant (1 $\mu$ M) for 24 hours and ERE-luciferase activity assessed. 2-way repeated measures ANOVA with Sidak's multiple comparisons test, n=4 mean with SD, \*\*P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001.

793



795

# 796 Figure 5. Transcriptomic analysis of *ESR1* mutant models

A, Gene set enrichment analysis for D538G+F404L models compared to D538G D6C
cells maintained in 1nM estradiol. Pathways highlighted red, false discovery rate
adjusted q value <0.05.</li>


800 B, Gene set enrichment analysis for D538G+F404L models compared to D538G D6C 801 cells treated with  $1\mu$ M fulvestrant for 24hr. Pathways highlighted red, false discovery 802 rate adjusted q value <0.05.

803 C, Gene Set Enrichment Analysis (GSEA) for *ESR1* mutant models. Normalised 804 enrichment score (NES) is shown for the indicated pathways. \*False discovery rate 805 adjusted q value <0.05.

B06 D, Heat map of "Estrogen response late" genes (Log2 expression) for *ESR1* mutant
models maintained in 1nM estradiol.

808 E, Heat map of "Estrogen response late" genes (Log2 expression) for *ESR1* mutant 809 models treated with  $1\mu$ M fulvestrant in presence of 1nMestradiol.

Figure 6



# 812 Figure 6. Compound F404 mutations are sensitive to novel SERDs.

A-D. Compound mutations of D538G-F404L in MCF7 cells, along with single mutations and wildtype, with sensitivity to elacestrant (A), camizestrant (B), 4OH tamoxifen (C) and giredestrant (D), assessed after 6 days treatment with Cell Titre Glo viability assay. N=4 mean with SD.

817 E. Representative clonongenic assays grown in indicated concentrations of 818 elacestrant, camizestrant, 4OH tamoxifen and giredestrant for 14 days.

F. MCF7 cells were co-transfected with the indicated *ESR1* expression constructs ERE-luciferase reporter and control construct. Cells were treated with indicated concentrations of fulvestrant, elacestrant, camizestrant, 4OH tamoxifen and giredestrant, in the presence of 1nM estradiol, for 24 hours and ERE-luciferase activity assessed. 2-way repeated measures ANOVA with Sidak's multiple comparisons test, n=3 mean with SD, \*P<0.05.